{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To estimate the time to transformation to AML in patients with \\<20% blasts. In patients with less than 20% blasts, the time to transformation to AML will be defined as the date of the first dose of drug until either the percentage of bone marrow blasts or the percentage of peripheral blasts exceeds 20%, whichever is first.","groups":[{"description":"Treatment to be administered on an outpatient basis. All participants to be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles.","id":"OG000","title":"Experimental: PF-04449913 Treatment"}],"populationDescription":"NA- The median time to AML was not reached due to insufficient number of participants with events.","reportingStatus":"POSTED","timeFrame":"Up to 2 years, 4 months","title":"Median Time to Transformation to Acute Myeloid Leukemia (AML)","type":"SECONDARY"}